During the past decade, Instytut Hematologii i Transfuzjologii; Klinika Hematologii conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 4 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instytut Hematologii i Transfuzjologii; Klinika Hematologii" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Celgene" with 2 trials sponsored, "Affimed GmbH" with 1 trials sponsored, "Gilead Sciences" with 1 trials sponsored and "Moleculin Biotech, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instytut Hematologii i Transfuzjologii; Klinika Hematologii" #1 collaborator was "Onxeo" with 1 trials as a collaborator and "UCB Pharma" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Instytut Hematologii i Transfuzjologii; Klinika Hematologii" are "Diffuse Large B-cell Lymphoma" (2 trials), "Acute Lymphoblastic Leukemia" (1 trials), "Anemia" (1 trials), "Follicular Lymphoma" (1 trials) and "Leukemia, Myeloid, Acute" (1 trials). Many other conditions were trialed in "Instytut Hematologii i Transfuzjologii; Klinika Hematologii" in a lesser frequency.

Most popular intervention types in "Instytut Hematologii i Transfuzjologii; Klinika Hematologii" are "Drug" (10 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Lenalidomide" (2 trials), "Placebo" (2 trials), "Tocilizumab" (2 trials), "AFM13" (1 trials) and "Belinostat" (1 trials). Other intervention names were less common.

The vast majority of trials in "Instytut Hematologii i Transfuzjologii; Klinika Hematologii" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Instytut Hematologii i Transfuzjologii; Klinika Hematologii". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Instytut Hematologii i Transfuzjologii; Klinika Hematologii, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Instytut Hematologii i Transfuzjologii; Klinika Hematologii, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".